Quantcast

Latest Pharmacogenetics Stories

2010-02-21 13:11:41

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy (IGSP) have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free. They say the discovery, appearing online in the journal Nature, opens the door...

2010-02-10 08:24:00

LONDON, February 10 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce the launch of its expanded web site. The site, which was designed by Opus Design Consultants, highlights how pharmacogenetics can help to target drugs to those patients most likely to benefit, and to increase safety and cost-effectiveness. Working in partnership with its seven founding academic institutions, all with...

2009-10-30 10:24:00

LONDON, October 30 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September(1). The meeting recognised that while pharmacogenetics and genetics have great potential in helping the biopharmaceutical industry overcome its many challenges, early clinical collaboration between companies, academia, regulators...

2009-10-26 15:14:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Pharmacogenomics: Delivering on the Promise http://www.reportlinker.com/p0156560/Reportlinker-Adds-Pharmacogenomics-Delivering-on-the-Promise.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Pharmacogenomics (PGx) is often considered "the great new wave" in medicine, promising better, safer, and more affordable healthcare....

2009-10-22 07:45:00

CINCINNATI, Oct. 22 /PRNewswire/ -- AssureRx, a personalized medicine company, announced today that it has begun a full launch of its first product, GeneSightRx(TM) This lab-developed, pharmacogenetic test had previously been commercially available only on a limited basis. The test combines state-of-the-art genetic testing technology with a multi-variate, algorithmic, interpretive report to help guide physicians during their decision-making process before prescribing psychiatric...

2009-09-18 10:05:00

LONDON, September 18 /PRNewswire/ -- London Genetics Limited, which expedites pharmacogenetic partnerships between the biopharmaceutical industry and London-based centres of excellence in genetics research, announces today several prestigious appointments to its Board and management team. The new appointments, which include Dr Barrie Ward as Chairman, will drive the next phase of the company's growth as the importance of pharmacogenetics in drug development increases. They bring important...

2009-08-26 14:14:00

A gene variant carried by about one-third of the population plays a major role in how they respond to an anti-clotting medicine, U.S. researchers said. Rochelle M. Long, director of the National Institutes of Health Pharmacogenetics Research Network, said people with the variant produce a defective version of the CYP2C19 enzyme and are less able to activate the drug clopidogrel, also known as Plavix. Long said Plavix, one of the world's best-selling medicines, prevents blood clots in...

2009-06-09 08:00:00

Experienced Executive to Lead Personalized Medicine Company in Next Phase of Growth CINCINNATI, June 9 /PRNewswire/ -- AssureRx, a personalized medicine company, announced today that James S. Burns has joined the Mason-based company as its new President and CEO. Burns comes to AssureRx with more than 30 years of executive experience in the strategic management of science and technology for pharmaceutical, diagnostic, and biotech companies. Most recently, he was president and CEO of...

2009-06-01 07:14:22

 The International Serious Adverse Events Consortium (SAEC) announced today initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI). The SAEC is a nonprofit research corporation, launched in the fall of 2007, comprised of and funded by 10 leading pharmaceutical companies and the Wellcome Trust. The U.S. Food and Drug Administration (FDA) also contributes to the scientific and strategic...

2009-02-18 08:00:00

Study Suggests Genetic Approach to Personalized Screening of Anti-Rejection Drug Dosing CINCINNATI, Feb. 18 /PRNewswire-USNewswire/ -- Screening for mutations in a gene that helps the body metabolize a kidney transplant anti-rejection drug may predict which children are at higher risk for side effects, including compromised white blood cell count or organ rejection, according to new research. Published online Feb. 18 by the Nature journal Clinical Pharmacology and Therapeutics, the study...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related